bluuebunny/crossref_metadata_2025_split huggingface dataset:
Computer vision syndrome and its determinants: A systematic review and meta-analysis
Authors: Lema Asamene Kelelom , Anbesu Etsay Woldu 
Published: December 2022

Objective: Computer vision syndromes are becoming a major public health concern. Inconsistent findings existed on computer vision syndrome. This systematic review and meta-analysis aimed to estimate the pooled prevalence of computer vision syndrome and identify its determinants. Methods: In this study, the review was developed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Online electronic databases, including PubMed/Medline, CINAHL, and Google Scholar, were used to retrieve studies from 1 December to 9 April 2022. Quality assessment of the studies was performed using the JBI-MAStARI. RevMan and STATA 14 software were used for statistical analysis. Result: A total of 725 studies were retrieved, and 49 studies were included. The pooled prevalence of computer vision syndrome was 66% (95%, Confidence interval: 59, 74). Being female (Odd Ratio = 1.74, 95% Confidence interval [1.2, 2.53]), improper body posturing while using electronic devices (Odd Ratio = 2.65, 95% Confidence interval [1.7, 4.12]), use of electronic devices out of work (Odd Ratio = 1.66, 95% CI [1.15, 2.39]), no habit of taking breaks (Odd Ratio = 2.24, 95% Confidence interval [1.13, 4.44]), long duration of visual display terminal use (Odd Ratio = 2.02, 95% Confidence interval [1.08, 3.77]), short distance screen (Odd Ratio = 4.24, 95% Confidence interval [2.33, 7.71]), and general ergonomic practice (Odd Ratio = 3.87, 95% Confidence interval [2.18, 6.86]) were associated with increased odds of computer vision syndrome. However, good knowledge (Odd Ratio = 4.04, 95% Confidence interval [2.75, 5.94]) of computer vision syndrome was associated with decreased odds of computer vision syndrome. Conclusion: Nearly two in three participants had computer vision syndrome. Being female, improper body posturing, use of electronics devices out of work, no habit of taking a break, long-hour duration of visual display terminal use, short-distance screen, and general ergonomic practice were associated with increased odds of computer vision syndrome.
Correlation of Tibial Torsion With Lower Limb Alignment and Femoral Anteversion in Patients With Patellar Instability
Authors: Qiao Yi , Xu Junjie , Zhang Xiuyuan , Ye Zipeng , Wu Chenliang , Xu Caiqi , Zhao Song , Zhao Jinzhong 
Published: December 2022

Background: Alignment and rotation of the lower extremities have been suggested to be predisposing pathologic factors for patellar instability. Purpose: To elucidate the relationship between the lower limb alignment and lower extremity rotation in patients with patellar instability. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Included were 83 patients with patellar instability. Computed tomography scans and standing full-leg radiographs were used to measure the tibial tuberosity–trochlear groove (TT-TG) distance, mechanical femorotibial angle (mFTA), mechanical lateral distal femoral angle (mLDFA), mechanical medial proximal tibial angle (mMPTA), femoral torsion, and tibial torsion of the different segments. The relationships between femoral torsion, tibial torsion of the different segments, and the mFTA, mLDFA, and mMPTA were evaluated. The levels of tibial torsion and femoral torsion in patients with varus, normal, or valgus alignment were compared with 1-way analysis of variance and chi-square test. Results: The total tibial torsion was significantly associated with total femoral anteversion ( r = 0.329; P = .002) and mFTA ( r = –0.304; P = .005). There were no significant correlations between mFTA and TT-TG distance or femoral anteversion. Compared with patients with valgus malalignment, patients with varus malalignment tended to have higher tibial torsion. Conclusion: Tibial torsion was associated with leg axis alignment and femoral anteversion in patients with patellar instability. Patients with patellar instability, especially those with concurrent leg axis deformities, should undergo further radiological imaging so that tibial torsion can be assessed and a diagnosis of torsion deformity made early in the treatment pathway and the proper surgical plan formulated.
Selsurtite, (H3O)12Na3(Ca3Mn3)(Na2Fe)Zr3□Si[Si24O69(OH)3](OH)Cl⋅H2O, a new eudialyte-group mineral from the Lovozero alkaline massif, Kola Peninsula, Russia
Authors: Chukanov Nikita V. , Aksenov Sergey M. , Kazheva Olga N. , Pekov Igor V. , Varlamov Dmitry A. , Vigasina Marina F. , Belakovskiy Dmitry I. , Vozchikova Svetlana A. , Britvin Sergey N. 
Published: December 2022

AbstractThe new eudialyte-group mineral selsurtite, ideally (H3O)12Na3(Ca3Mn3)(Na2Fe)Zr3□Si[Si24O69(OH)3](OH)Cl⋅H2O, was discovered in metasomatic peralkaline rock from the Flora mountain, northern spur of the Selsurt mountain, Lovozero alkaline massif, Kola Peninsula, Russia. The associated minerals are aegirine, albite and orthoclase, as well as accessory lorenzenite, calciomurmanite, natrolite, lamprophyllite and sergevanite. Selsurtite occurs as brownish-red to reddish-orange, equant or flattened on (0001) crystals up to 2 mm across and elongate crystals up to 3 cm long. The main crystal forms are {0001}, {11$\bar{2}$0}, and {10$\bar{1}$1}. Selsurtite is brittle, with the Mohs’ hardness of 5. No cleavage is observed. Parting is distinct on (001). D(meas) = 2.73(2) and D(calc) = 2.722 g⋅cm–3. Selsurtite is optically uniaxial (–), with ω = 1.598(2) and ɛ = 1.595(2). The chemical composition is (wt.%, electron microprobe): Na2O 6.48, K2O 0.27, MgO 0.10, CaO 6.83, MnO 4.73, FeO 1.18, SrO 1.88, La2O3 0.57, Ce2O3 1.07, Pr2O3 0.20, Nd2O3 0.44, Al2O3 0.29, SiO2 50.81, ZrO2 13.50, HfO2 0.45, TiO2 0.61, Nb2О5 1.10, Cl 1.01, SO3 0.29, H2O 8.10, –O≡Cl –0.23, total 99.68. The empirical formula is H25.94Na6.03K0.16Mg0.07Ca3.51Sr0.52Ce0.19La0.10Nd0.08Pr0.03Mn1.91Fe0.47Ti0.22Zr3.16Hf0.06Nb0.24Si24.40Al0.16S0.10Cl0.82O79.13. The crystal structure was determined using single-crystal X-ray diffraction data and refined to R = 0.0484. Selsurtite is trigonal, space group R3, with a = 14.1475(7) Å, c = 30.3609(12) Å, V = 5262.65(7) Å3 and Z = 3. Infrared and Raman spectra show that hydronium cations are involved in very strong hydrogen bonds and form Zundel- and Eigen-like complexes. The strongest lines of the powder X-ray diffraction pattern [d, Å (I, %)(hkl)] are: 11.38 (56)(101), 7.08 (59)(110), 5.69 (36)(202), 4.318 (72)(205), 3.793 (36)(303), 3.544 (72)(027, 220, 009), 2.970 (100)(315) and 2.844 (100)(404). The mineral is named after the discovery locality.
Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept
Authors: Hertz Laura , Flormann Daniel , Birnbaumer Lutz , Wagner Christian , Laschke Matthias W. , Kaestner Lars 
Published: December 2022

Abstract
For some molecular players in red blood cells (RBCs), the functional indications and molecular evidence are discrepant. One such protein is transient receptor potential channel of canonical subfamily, member 6 (TRPC6). Transcriptome analysis of reticulocytes revealed the presence of TRPC6 in mouse RBCs and its absence in human RBCs. We transfused TRPC6 knockout RBCs into wild-type mice and performed functional tests. We observed the “rescue” of TRPC6 within 10 days; however, the “rescue” was slower in splenectomized mice. The latter finding led us to mimic the mechanical challenge with the cantilever of an atomic force microscope and simultaneously carry out imaging by confocal (3D) microscopy. We observed the strong interaction of RBCs with the opposed surface at around 200 pN and the formation of tethers. The results of both the transfusion experiments and the atomic force spectroscopy suggest mechanically stimulated protein transfer to RBCs as a protein source in the absence of the translational machinery. This protein transfer mechanism has the potential to be utilized in therapeutic contexts, especially for hereditary diseases involving RBCs, such as hereditary xerocytosis or Gárdos channelopathy.
Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII
Authors: Zhang Yuan , Liu Zhigang , Zhang Bin 
Published: December 2022

AbstractMutations in lectin, mannose-binding 1 (LMAN1) and multiple coagulation factor deficiency protein 2 (MCFD2) cause the combined deficiency of factor V (FV) and FVIII (F5F8D). LMAN1 and MCFD2 form a protein complex that transports FV and FVIII from the endoplasmic reticulum (ER) to the Golgi. Although both proteins are required for the cargo receptor function, little is known about the specific roles of LMAN1 and MCFD2 in transporting FV/FVIII. We used different LMAN1 and MCFD2 deficient cell lines to investigate the LMAN1/MCFD2-dependent FV/FVIII secretion pathway. LMAN1 deficiency led to more profound decreases in FV/FVIII secretion in HEK293T and HepG2 cells than in HCT116 cells, suggesting that regulation of cargo transport by the LMAN1/MCFD2 pathway varies in different cell types. Using these cell lines, we developed functional assays to accurately assess the pathogenicity of recently reported potential LMAN1 and MCFD2 missense mutations. LMAN1 with mutations abolishing carbohydrate binding can still partially rescue FV/FVIII secretion, suggesting that N-glycan binding is not essential for FV/FVIII transport. Surprisingly, overexpression of either wild-type or mutant MCFD2 is sufficient to rescue FV/FVIII secretion defects in LMAN1 deficient cells. These results suggest that cargo binding and transport are carried out by MCFD2 and that LMAN1 primarily serves as a shuttling carrier of MCFD2. Finally, overexpression of both LMAN1 and MCFD2 does not further increase FV/FVIII secretion, suggesting that the amount of the LMAN1-MCFD2 receptor complex is not a rate-limiting factor in ER-Golgi transport of FV/FVIII. This study provides new insight into the molecular mechanism of F5F8D and the intracellular trafficking of FV and FVIII.
Sequencing therapy in relapsed DLBCL
Authors: Flowers Christopher R. , Odejide Oreofe O. 
Published: December 2022

Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of patients diagnosed with DLBCL are alive at 5 years and cured with modern therapy, but about 10% to 15% of patients are refractory to first-line therapy, and an additional 20% to 30% relapse following a complete response. Patients who have relapses beyond 2 years may experience more favorable outcomes and have forms of DLBCL that can be distinguished biologically. Patients who experience early relapse or who have primary refractory disease (less than a complete response or relapse within 3 to 6 months of initial therapy) have worse outcomes. For decades, the standard of care treatment strategy for fit patients with relapsed DLBCL has been salvage therapy with non–cross-resistant combination chemoimmunotherapy regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as stem cell rescue for patients with chemosensitive disease. Recent data suggest that certain patients may benefit from chimeric antigen receptor T-cell therapy (CAR T) in the second-line setting. Additional novel therapies exist for patients who are ineligible, who are unable to access these therapies, or who fail ASCT and/or CAR T. Despite the advent of new therapies for DLBCL and improved outcomes, DLBCL remains a life-threatening illness. Thus, it is essential for clinicians to engage in serious illness conversations with their patients. Goals-of-care communication can be improved through skills-based training and has been demonstrated to have an impact on patient experiences.
New approaches to tackle cytopenic myelofibrosis
Authors: Reynolds Samuel B. , Pettit Kristen 
Published: December 2022

Abstract
Myelofibrosis (MF) is a clonal hematopoietic stem cell neoplasm characterized by constitutional symptoms, splenomegaly, and risks of marrow failure or leukemic transformation and is universally driven by Jak/STAT pathway activation. Despite sharing this pathogenic feature, MF disease behavior can vary widely. MF can generally be categorized into 2 distinct subgroups based on clinical phenotype: proliferative MF and cytopenic (myelodepletive) MF. Compared to proliferative phenotypes, cytopenic MF is characterized by lower blood counts (specifically anemia and thrombocytopenia), more frequent additional somatic mutations outside the Jak/STAT pathway, and a worse prognosis. Cytopenic MF presents unique therapeutic challenges. The first approved Jak inhibitors, ruxolitinib and fedratinib, can both improve constitutional symptoms and splenomegaly but carry on-target risks of worsening anemia and thrombocytopenia, limiting their use in patients with cytopenic MF. Supportive care measures that aim to improve anemia or thrombocytopenia are often ineffective. Fortunately, new treatment strategies for cytopenic MF are on the horizon. Pacritinib, selective Jak2 inhibitor, was approved in 2022 to treat patients with symptomatic MF and a platelet count lower than 50 × 109/L. Several other Jak inhibitors are in development to extend therapeutic benefits to those with either anemia or thrombocytopenia. While many other novel non–Jak inhibitor therapies are in development for MF, most carry a risk of hematologic toxicities and often exclude patients with baseline thrombocytopenia. As a result, significant unmet needs remain for cytopenic MF. Here, we discuss clinical implications of the cytopenic MF phenotype and present existing and future strategies to tackle this challenging disease.
Allogeneic transplantation for advanced acute leukemia
Authors: Weisdorf Daniel 
Published: December 2022

Abstract
Outcomes of allogeneic hematopoietic cell transplantation (HCT) for patients with advanced acute leukemia and myelodysplastic syndromes (MDS) remain uncertain. All published series include the important and often not stated selection bias that influences outcome. Performance status, patient age, prompt donor availability, risk phenotype of the leukemia, and tumor burden all influence the decision-making process about HCT with active disease. In addition, patients with MDS do not achieve a true pre-HCT complete remission, and thus much less stringent measures are used to indicate suitability for allografting in that disease. Post-HCT maintenance or investigational approaches for tumor depletion may improve the outcomes.
Transplant in AML with measurable residual disease: proceed or defer?
Authors: Craddock Charles 
Published: December 2022

Abstract
Allogeneic stem cell transplantation plays a central role in the management of fit adults with high-risk acute myeloid leukemia (AML) in first complete morphologic remission (CR1). Advances in both donor selection and transplant technology have both dramatically increased accessibility of transplant and led to significant reductions in transplant-related mortality over the past 2 decades. There has, however, been no concomitant reduction in the risk of disease relapse, which remains the major cause of transplant failure. Pivotal to the design of innovative strategies with the potential to reduce relapse risk is accurate identification of patients at the highest risk of disease recurrence. Multiple retrospective studies have identified an increased risk of disease relapse in patients allografted for AML in CR1 with evidence of pretransplant measurable residual disease (MRD). The prognostic significance of pretransplant MRD has been confirmed recently in prospective analyses. The optimal management of patients with evidence of pretransplant MRD remains a matter of conjecture with regard to 2 key issues. First, should the presence of pretransplant MRD delay a decision to proceed to transplant, allowing time for delivery of additional MRD-directed therapy prior to transplant? Second, to what extent can the intensity of the conditioning regimen or the magnitude of the graft-vs-leukemia effect be manipulated to improve the outcome of such patients?
The first relapse in multiple myeloma: how to pick the next best thing
Authors: Devarakonda Srinivas , Sharma Nidhi , Efebera Yvonne 
Published: December 2022

Abstract
The choice of treatment for patients with multiple myeloma (MM) at first relapse/progression is based on many factors: (1) treatment-related factors, which include the regimen used during first induction, the quality and duration of first response achieved, toxicities from the first treatment, whether the patient underwent autologous stem cell transplant, and whether the patient was on maintenance at the time of relapse/progression; (2) disease-related factors, including disease presentation and pace of progression; and (3) patient-related factors, including functional age and performance status. The learning objectives are to present the treatment options for patients with MM upon their first relapse and to learn about various strategies for selecting an optimal treatment regimen.
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies
Authors: Pommert Lauren , Tarlock Katherine 
Published: December 2022

Abstract
Despite the maximum intensification of chemotherapy and the increased use of hematopoietic stem cell transplantation (HCT) in pediatric patients with acute myeloid leukemia (AML), nearly 40% of patients still experience relapse, and cure in this setting remains a significant challenge. Recent improvements in AML characterization, including advances in flow cytometry and comprehensive genomic sequencing, have led to a better understanding of AML biology and the identification of multiple potential therapeutic targets. Novel agents targeting genomic lesions, cell surface antigens, and other mechanisms that permit oncogenesis or immune escape are being incorporated into current treatment strategies or are under investigation in efforts to improve outcomes and decrease the toxicities and late effects associated with traditional intensive chemotherapeutic and HCT treatment. However, multiple challenges still exist, including the biologic and immunophenotypic heterogeneity of childhood AML, the differences in underlying biology as compared to adult AML, and the significant potential for on-target/off-tumor toxicity associated with therapies directed at targets common to myeloid cells, both leukemic and normal. This article reviews the current landscape of genomic and cell surface targets for children with AML with a focus on the currently available targeted therapeutic agents, those in active clinical investigation, and those still in development.
Divergent paths: management of early relapsed follicular lymphoma
Authors: Takiar Radhika , Karimi Yasmin , Phillips Tycel J. 
Published: December 2022

Abstract
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in the United States and Western Europe. Overall outcomes for patients with FL have continued to improve over the last several decades—most notably, with the addition of the CD20 monoclonal antibody rituximab to the treatment armamentarium. More recently, we have seen advances in the management of patients with relapsed/refractory FL with the approval of several new treatments including lenalidomide, axicabtagene ciloleucel, copanlisib, umbralisib, and tazemetostat. Unfortunately, there remains a group of patients for which treatment outcomes, especially overall survival (OS), are suboptimal. This group has been identified as patients who relapse within 24 months (POD24) of completion of chemoimmunotherapy (CIT). Data indicate that patients who relapse within this window have a 5-year OS of around 50%, compared to 80% for those who remain in remission beyond 24 months. POD24 patients have been included and evaluated in the studies of the novel agents mentioned. While not specifically designed to treat this high-risk group, early data suggest that outcomes are not significantly impacted by this designation, unlike CIT. While to date the optimal management of POD24 patients has not been elucidated, the future appears bright with the continued use of the approved agents and several others in clinical development.
Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism
Authors: Cohen Omri , Ageno Walter 
Published: December 2022

AbstractAnticoagulants have been in use for nearly a century for the treatment and prevention of venous and arterial thromboembolic disorders. The most dreaded complication of anticoagulant treatment is the occurrence of bleeding, which may be serious and even life-threatening. All available anticoagulants, which target either multiple coagulation factors or individual components of the tissue factor (TF) factor VIIa or the common pathways, have the potential to affect hemostasis and thus to increase bleeding risk in treated patients. While direct oral anticoagulants introduced an improvement in care for eligible patients in terms of safety, efficacy, and convenience of treatment, there remain unmet clinical needs for patients requiring anticoagulant drugs. Anticoagulant therapy is sometimes avoided for fear of hemorrhagic complications, and other patients are undertreated due to comorbidities and the perception of increased bleeding risk.Evidence suggests that the contact pathway of coagulation has a limited role in initiating physiologic in vivo coagulation and that it contributes to thrombosis more than it does to hemostasis. Because inhibition of the contact pathway is less likely to promote bleeding, it is an attractive target for the development of anticoagulants with improved safety.Preclinical and early clinical data indicate that novel agents that selectively target factor XI or factor XII can reduce venous and arterial thrombosis without an increase in bleeding complications.
Special considerations in GI bleeding in VWD patients
Authors: Chornenki Nicholas L.J. , Ocran Edwin , James Paula D. 
Published: December 2022

Abstract
Gastrointestinal (GI) bleeding is an important cause of morbidity and mortality in von Willebrand disease (VWD). It has been noted that GI bleeding caused by angiodysplasia is overrepresented in VWD patients compared to other causes. The bleeding from angiodysplasia is notoriously difficult to treat; recurrences and rebleeds are common. A growing body of basic science evidence demonstrates that von Willebrand factor negatively regulates angiogenesis through multiple pathways. VWD is clinically highly associated with angiodysplasia. The predisposition to angiodysplasia likely accounts for many of the clinical difficulties related to managing GI bleeding in VWD patients. Diagnosis and treatment are challenging with the current tools available, and much further research is needed to further optimize care for these patients with regard to acute treatment, prophylaxis, and adjunctive therapies. In this review we provide an overview of the available literature on GI bleeding in VWD and explore the molecular underpinnings of angiodysplasia-related GI bleeding. Considerations for diagnostic effectiveness are discussed, as well as the natural history and recurrence of these lesions and which therapeutic options are available for acute and prophylactic management.